Stock Financial Ratios and Split History

ADRO / Aduro Biotech, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)745.26
Enterprise Value ($M)591.70
Book Value ($M)237.47
Book Value / Share2.93
Price / Book3.14
NCAV ($M)149.31
NCAV / Share1.84
Price / NCAV4.99
Income Statement (mra) ($M)
Net Income-91.86
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Quick Ratio10.13
Current Ratio10.13
Share Statistics
Common Stock Shares Outstanding77,736,201
Common Shares Outstanding81,006,486
Preferred Stock Shares Outstanding0
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.39
Return on Assets (ROA)-0.21
Return on Equity (ROE)-0.40
Identifiers and Descriptors
Central Index Key (CIK)1435049
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Related CUSIPS
00739L901 00739L951

Split History

Stock splits are used by Aduro Biotech, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers - Pharmaceutical Preparations (2834)

Related News Stories

Aduro (ADRO) Q4 Loss Narrower Than Expected, Revenues Miss

2018-03-05 zacks
Aduro Biotech, Inc. (ADRO - Free Report) reported fourth-quarter 2017 loss of 34 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 36 cents and the year-ago loss of 44 cents. (29-2)

The 10 Best ETFs of February 2018

2018-02-28 investorplace
February was a crazy month for investors; consequently, the landscape of best-performing exchange-traded funds expanded from primarily biotech and emerging-market ETFs in January to several other spaces for this edition of the best ETFs of the month. (332-2)

Armo BioSciences: Analysis And Valuation Of Recent Immune-Oncology IPO

2018-02-22 seekingalpha
Armo BioSciences is a Silicon Valley-based immune-oncology company that recently launched its $128M IPO on Nasdaq. (88-0)

CUSIP: 00739L101